Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00265148 · ClinicalTrials.gov registry record · Phase 2
Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00265148 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 80 participants.
The verdict
NCT00265148, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
This is a placebo-controlled study evaluating the effects of rosiglitazone on functional brain activity and cognition in patients with mild to moderate Alzheimer's Disease (AD).
Interventions
- OTHER Placebo
- DRUG Rosiglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2004-05-18 |
| Est. Completion | 2008-07-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00265148
The ClinicalTrials.gov registry entry for NCT00265148 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00265148 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00265148 about?
NCT00265148 is a clinical study titled "Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease". This is a placebo-controlled study evaluating the effects of rosiglitazone on functional brain activity and cognition in patients with mild to moderate Alzheimer's Disease (AD).
What is the current status of trial NCT00265148?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2004-05-18. Estimated completion is 2008-07-10.
What interventions are being tested in trial NCT00265148?
The interventions under investigation include: Placebo (OTHER), Rosiglitazone (DRUG).
Who is sponsoring clinical trial NCT00265148?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.